3 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
Follow albuvirtide: new trials by email Literature Review of albuvirtide trials Research Report on albuvirtide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection Albuvirtide, 3BNC117 Antibody - HIV/AIDS | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 20 | 2021-11-30 | 2021-09-29 |
| Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection Albuvirtide, 3BNC117 - HIV/AIDS | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 24 | 2021-05-01 | 2021-03-26 |
| Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects Albuvirtide, 3BNC117, Baseline ART - HIV-1-infection | Phase 2 | Unknown | Frontier Biotechnologies Inc. | 80 | 2018-12-17 | 2021-09-29 |
Acquired Immunodeficiency Syndrome (2)
Frontier Biotechnologies Inc. (3)
United States (2) · China (1)
Cheng Yao (1) · Cheng Yao, M.D. (1)